SAPA-GP's History
The Sino-American Pharmaceutical Professionals Association (SAPA) was founded in 1993 as a non-profit organization. SAPA has grown rapidly and has become one of the most active and well recognized professional organizations in the United States. SAPA's membership base now stands at approximately 4,000 scientists and researchers in the United States.
The Greater Philadelphia (GP) area is one of the major homes for the world pharmaceutical industry. It hosts more than half of the world's top-ten pharmaceutical companies, and many mid/small pharmaceutical/biotech companies as well as academic institutions. SAPA-GP was established in 2002 to serve the rapidly growing pharmaceutical/biotech/healthcare community in the GP area.
SAPA-GP's Mission
To serve its membership, the pharmaceutical sciences, the biomedical and biotechnological community, the health professions, and the interest of the public health by:
-Promoting all aspects of the pharmaceutical and biopharmaceutical sciences, including both academic as well as industrial interests and providing for recognition of individual achievement; -Fostering education, career growth and the personal development of its members; -Providing a forum for open interchange and dissemination of scientific knowledge; -Bridging and developing the relationship in the pharmaceutical area between the US and China.
6 SAPA-GP Accomplishments (2013) (2014) In 1984, Dr. Bennett founded ATI Centers, Inc., which consisted of 13 outpatient diagnostic imaging and physical therapy centers located throughout Pennsylvania and New Jersey. Fueled by immediate interest in the company, Dr. Bennett and a handful of employees set out to build a preferred provider organization (PPO) with services to encompass all provider specialties -and succeeded. The company was renamed Devon Health Services, Inc. in 1995 and is now the largest privately owned PPO in the Northeast United Sates.
The success of Devon Health has given Dr. Bennett the opportunity to expand into the different sectors of what now comprise the DIG group of companies. Consilium is an out-of-network healthcare claims company that uses expert negotiation and a proprietary, patent-pending business intelligence software tool to generate substantial savings for customers. Devon IT is a technology company and the world's third largest provider of software that manages thin client desktop devices. Devon Medical Products is a global designer and manufacturer of medical devices used to treat wounds, complications from diabetes, and other health complications. And DIG also has various other entities operating in various verticals worldwide. Dr. Bennett preaches the "Blue Ocean Strategy" -developing new markets rather than competing in bloody, competitive ones -and "The World is Flat" -conducting business on an international scale. Today DIG has over 500 employees operating in 22 countries.
Dr. Bennett is a true entrepreneur who identifies unique products and services that enhance global business. His work takes him throughout the world, where his international relationships and business partnerships help drive revenue in domestic markets. He has published over 320-refereed manuscripts, which have been cited over 13,000 times, and he has an h-index of 58.
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Co-founder and Chief Executive Officer, PTM Biolabs Dr. Zhongyi Cheng (Jack) is the Chief Executive Officer and co-founder of PTM Biolabs, Inc. Dr. Cheng has his expertise in protein post translational modifications (PTMs), epigenetics, and proteomics. In the past five years, Dr. Cheng has co-authored over 10 peer reviewed publications in the field of PTM proteomics for biomarker discovery and drug target screening. Dr. Cheng holds a PhD in Molecular and Cell Biology from the University of Science and Technology of China. He received his postdoctoral training at the University of Texas Southwestern Medical Center at Dallas and University of Chicago. Dr. Cheng co-founded PTM Biolabs in 2010 and has since led the organization to become the leading developer for high quality antibodies against specific PTM pathways and histone marks. He has also co-developed high sensitivity PTM proteomic technology and applied it to preclinical pharmaceutical research and development. This integrated technology has profoundly advanced drug discovery process, especially for candidates targeting epigenetic mechanisms. In January 2009, Guy was promoted to Senior Vice President and Managing Director for MSD in France. He successfully led this $ 2 billion & three thousand employee organization through 4 years of turbulent times with profound restructuring and reorganization following the merger between Merck and Schering-Plough. In January 2013, Guy was promoted to lead MSD MidEurope Region, a 20-country region in Europe gathering mid-size markets from the Netherlands to Portugal and from Greece to all Eastern European markets. Since November 2013, Guy is the Managing Director of a new entity, wholly owned by Merck, named Healthcare Solutions & Services (HSS). HSS is aimed at developing and commercializing globally a portfolio of services and solutions to add value to all stakeholders in the healthcare environment.
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Guy is married to Noelle and has three children. Jeffrey Hung, PhD, is the Vice President of GenScript, a leading biology research service company in the world. Jeff, an innovative leader in growing startup companies, is responsible for gene synthesis applications. Jeff was the chief marketing officer at ATCC before joining GenScript. Prior to that role, he served as the Senior Director of Marketing at SABiosciences, growing the company rapidly, and was instrumental for the acquisition of SABiosciences by QIAGEN. He has held management and R&D positions at Invitrogen, Havard Bioscience and Exelixis. Jeff earned his PhD from Cornell University, MBA from UC Berkeley, and BS from Peking University. Professionally, Dr. Li has held responsible roles in the area of drug discovery metabolism at MDS Pharma Services (a major CRO), in the Drug Analysis group in the Department of Drug Metabolism and Pharmacokinetics (DMPK) at GSK Pharmaceuticals and in the Drug Metabolism group at Cephalon. Dr. Li has extensive DMPK experience in both drug discovery and development. He is a recognized expert in the field of bioanalysis and DMPK. He has more than 15 years of working experience in CRO, pharmaceutical and biotech industries. SZ002422) . In this position, Wenjia focuses on evaluating projects provided by sponsors based on many aspects such as the patent state, technical issue and the registration problem to provide advice by evaluation report and final project evaluating presentation. In addition, she is getting started with building up the internal training department, preparing for research center size expansion, hosting and planning internal and external meeting, and conducting the daily management of Pharmacology Department.
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scientist to develop and optimize large scale antibiotic manufacturing processes within SmithKline Beecham Pharmaceuticals (GSK). In 2001, Linden moved to the US to join the Biopharmaceutical development organization within GSK to focus on the development, registration
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Previously, Wenjia worked as Data Coordinator (Clinical Trial) in MSD data management center, one of the four in global range to provide the clinical data management supporting work of MSD, where she took part in every step of clinical trial and was responsible for the entire project after 6 months (the Data Project Lead).
Before joining MSD, Wenjia was a DMPK Scientist in BioDuro. She worked on analyzing the organic compound in low MW using LC/MS/MS, LC, and GC of all kinds of samples, especially method establishment and validation, followed by a QA Auditor in BioDuro with audit work of GLP lab (taking charge of the pre-clinical toxicology study data review), preparing data files in the founding of QAU and writing, revising and proof-reading of SOPs. Dr. Morris has significantly contributed to graduate and postdoctoral education through her contributions as Associate Dean for Graduate and Postdoctoral Education in the Graduate School as the University at Buffalo (2006 Buffalo ( -2012 . She has also been or currently is the major advisor to 28 PhD students, 11 MS, 6 BS/MS students, 10 postdoctoral scholars and many PharmD and undergraduate students. Dr. Murray comes to Merck with two decades of experience in the Biologics arena from basic to translational research, overseeing clinical and commercial scale manufacturing, and supporting the supply chain of hospital based products. His experience spans from co-founding startup companies, leadership roles in mid-sized biotech companies, to his current role overseeing multiple sub-divisions of MRL.
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Prior to joining Merck, Dr. Murray provided strategic and operational guidance to protein therapeutic biotech companies and served as an advisor to venture capital and life science investors. Dr. Murray was the prior EVP and CSO at PDL BioPharma. Previously, he was cofounder and VP of research at EOS Biotechnology. Prior to executive level roles, he spent over 10 years on the staff at DNAX Research Institute, which later became Schering Plough Biopharma, and now represents the main site for Merck's Biologics discovery efforts.
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Executive Director, Montgomery County Development Corporation David A. Niles is the Executive Director of the Montgomery County Development Corporation (MCDC), which has been newly reconstituted as a partnership between the organization's private sector membership and Montgomery County's Commerce Department. David's role is to provide a single point of contact, with one phone call access to resources that have allowed county businesses to thrive in a very competitive region. David's organization has cooperated with the Redevelopment Authority to create competitive loans, Industrial Development Authority for cost effective training programs and with the Workforce Investment Board for creating a stronger and more effective county labor market.
Prior to his success with Economic Development initiatives in Montgomery County, Mr. Niles spent thirteen years in Commercial Real Estate. A significant amount of his energy was channeled into gaining a strong regional foothold in the life sciences, biotechnology and medical device sectors. David's collaborative abilities lead to an extremely effective partnership network among PA Department of Community and Economic Development (DCED, Pennsylvania Biotechnology Organization (PABio), BioStrategy Partners (BioSp) and Innovation x Ideas Network (i2n). These networks not only provided access to industry experts, but linking connections to service providers as well. Mr. Niles sits on the Board for both BioSP and i2n. Through BioStrategy Partners and i2n, Mr. Niles was able to consult for several University based Tech Transfer Offices (TTO). The initiatives of the TTO's, BioSP and i2n are the foundation of economic development in the purest form.
Today, in Mr. Niles capacity as Executive Director of MCDC, he has been instrumental in developing two new economic development initiatives in Montgomery County. A Municipal Services platform focused on providing consulting services to the 62 Communities within Montgomery County as well as The Manufacturing Alliance of Bucks County and Montgomery County. The Alliance is goal oriented and provides a 'one stop' shop/call for small (75 employees or less) manufacturing companies in Bucks and Montgomery Counties. The ultimate goal of creating economic value for businesses has been accomplished through the joint efforts of David's partners in Real Estate, township supervisors in the county communities and regional service providers supporting the manufacturing alliance.
Mr. Niles resides in Narberth with his wife Dana and his three children, Tyler, Lukas and Lily. During the work of the Committee Organization Department, Mr. Qian has put forward the idea of constructing China Optics Valley talent zone, which is supported by the municipal Party Committee Organization Department and Wuhan Personnel Bureau. He is actively involved in title evaluation, expert recommendation, and introduction of talents, creating a good environment in East Lake Hi-tech Development Zone for the recruitment and retention of talents.
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As the director of Education Culture and Public Health Bureau, Mr. Qian has contributed creative thinking and efforts to the construction of school culture, teachers and personnel system reform, the balanced development of the school, the school performance management, and the implementation of quality education.
At present, Mr. Qian is in charge of the introduction and incubation of Wuhan Institute of Biotechnology innovation group, and the construction and management of the public equipment sharing center.
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Head of Research and Non-Clinical Development, Shire Albert is a human geneticist with more than 17 years of scientific and leadership experience in drug discovery and development. Albert joined Shire in April of 2011 and currently he is the Head of Research and Nonclinical Development (RNCD) at Shire. He is accountable for the strategy and operational direction of the RNCD Organization and has the responsibility for initiating new internal research programs, external partnerships to enrich the R&D portfolio, and transitioning programs from Research into Development. Prior to joining Shire, Albert held various leadership positions at Pfizer where his team applied human genetics and computational biology to discover and develop novel therapeutics targeting diabetes, inflammatory diseases, and cancer. Albert received his PhD in Human Genetics at the University of Pittsburgh, an MS in Molecular Genetics from Johns Hopkins University and his BA in Biology from the University of Delaware. Squibb Co. in New Brunswick, NJ. Joe was responsible for building the manufacturing capabilities needed to supply the company's biologic medicines to worldwide markets, including the construction of the company's new $750 million large-scale multi-product bulk biologics manufacturing facility in Devens, Massachusetts, and the integration of Medarex, Inc. He has spent over 30 years in the pharmaceutical industry, focused primarily on the research, development, registration and commercialization of biopharmaceutical products made using recombinant DNA technology. He holds 13 patents and has several patent applications pending for biologic products.
Joe earned a BS degree in Chemistry from Southeast Missouri State University and a PhD degree in Biochemistry from the University of Tennessee Center for the Health Sciences. After receiving his PhD, Joe was awarded a post-doctoral fellowship in Molecular Biology at the prestigious Roche Institute of Molecular Biology, in Nutley, NJ.
Following his fellowship, Joe was hired to be a senior scientist to develop the large-scale protein purification processes necessary for the manufacture of Recombinant Protein Therapeutics. Interferon Sciences, Inc. recruited Dr. Tarnowski 
Patrick Toomey US Senator for Pennsylvania
Senator Pat Toomey is a leader on economic, financial services, and budget issues. He is known as a champion of fiscal responsibility.
The Philadelphia Inquirer wrote that Senator Toomey has emerged as "a leading voice on money matters." He helped write and enact the bipartisan JOBS Act, which cuts regulatory burdens on small and medium-sized businesses making it easier for them to raise capital and create jobs.
The senator serves on the Finance; Banking; Budget; and Joint Economic committees. Sen. Toomey is the chairman of the Senate Steering Committee -the coalition of Republican senators that advocates for innovative, conservative policies.
Sen. Toomey previously was elected to the House of Representatives and fulfilled his three-term pledge. In addition to his public service, the senator also was the president of the Club for Growth, owned and operated a small restaurant chain in the Lehigh Valley, and worked in the financial services industry. With nearly 20 years of pharmaceutical development experience, Dr. Wang's CMC operational oversight spans organic synthesis, formulation development, GMP analytical testing, and GMP manufacturing of clinical trial materials. Prior to joining Frontage in February 2007, Dr. Wang served as the director of analytical/QC at NovaDel Pharma Inc., where she led teams in providing support for NDA product development, clinical supplies manufacturing, CMC sections of regulatory filings, and technology transfer to commercial manufacturing sites. Prior to NovaDel, Dr. Wang headed pharmaceutical analysis and control group at Therics Inc. in product development for 510(k) and IND filings. Earlier in her career, Dr. Wang was a lecturer at the Graduate University of Chinese Academy of Science.
Dr. Wang earned a doctor of philosophy degree in chemistry with honors from Iowa State University followed by postdoctoral research at the University of Chicago. She received a master's degree in chemical engineering from Chinese Academy of Science and a bachelor's degree in chemistry from Peking University in China.
Lichun Wang, MS Vice-President, Kelun Pharmaceutical Research Institute
Lichun Wang is Vice-President of Kelun Pharmaceutical Research Institute of Kelun Pharmaceutical, a pharmaceutical company headquartered in Chengdu, Sichuan and listed at Shenzhen Stock Exchange (SZ002422). In this capacity, Lichun Wang has applied for over 63 patents (45 invention patents), in which 34 patents were granted (27 invention patents). As a project leader and the main researcher, Lichun Wang was responsible for two projects named Kelun Incubator of new drug research and the innovation of Fat Emulsion Injections, both of which were national R&D projects. In addition, the project of bock greenbrier rhizome soft capsule gets the third prize of Sichuan Science and Technology Progress Award. He has completed 10 NDA applications and 4 IND applications.
Lichun Wang also serves as the deputy director of the local large volume injection Engineering Technical Research Center, the deputy director of the local large volume injection State Local United Engineering Laboratory, the office manager of State Identifying Enterprise Technology Center. He enjoys the special government allowances of Chengdu city and is the member of Innovator Talent With over thirty years of experience working in the chemical industry, she enjoyed many years working for Dow Chemical R&D as well as Dow Plastics Marketing forging partnerships between industry, education, government and communities. Dr. Wu also has entrepreneurial experience with various small chemical companies and startups including "Science is Fun!" which she founded to engage young students in the excitement of science and enhance public awareness of the importance of supporting and improving science education.
As an ACS member for over forty years, Dr. Wu has served in many leadership roles at both the local and national levels for the American Chemical Society. Dr. Wu was elected to the ACS Board of Directors in 2006 and served as Director-at-Large until 2011. In 2011, she was elected to the Presidential succession of the American Chemical Society. As ACS President-Elect for 2012, she was invited to give plenary lectures worldwide and was made an honorary member of both the Romanian Chemical Society and the Polish Chemical Society. She traveled the world visiting chemistry communities as ACS President in 2013 and Immediate Past President in 2014.
Dr. Wu serves on the University of Illinois Chemistry Alumni Advisory Board, the International Advisory Board for the 45th IUPAC World Chemistry Congress 2015, and the Board of Directors for the Chinese-American Chemical Society. She holds 7 US Patents and has published a polymer textbook chapter and numerous articles in a variety of journals and magazines over the years.
Dr. Wu is co-editor of three ACS Symposium Books based on her ACS presidential symposia to be published in 2014 and 2015 and continues to share her message of "Partners for Progress and Prosperity" with science and technology communities worldwide.
